HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hanania, N. A. Articles by Donohue, J. F. Search for Related Content PubMed PubMed Citation Articles by Hanania, N. A. Articles by Donohue, J. F.

Pharmacologic Interventions in Chronic Obstructive Pulmonary Disease

Bronchodilators

¹ Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, Texas; and ² Section of Pulmonary and Critical Care Medicine, University of North Carolina, Chapel Hill, North Carolina

Correspondence and requests for reprints should be addressed to Nicola A. Hanania, M.D., Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, 1504 Taub Loop, Houston, Texas 77030. E-mail: hanania{at}bcm.edu

ABSTRACT

Chronic obstructive pulmonary disease (COPD) is a treatable disease characterized by progressive airflow limitation. Prevention of disease progression, improvement of symptoms, exercise tolerance, health status, and decrease in exacerbations and in mortality are the main goals of the management of COPD. Bronchodilators play a pivotal role in the treatment of symptomatic patients with COPD. Inhaled short-acting bronchodilators are currently recommended for rescue of symptoms in patients with mild disease, whereas inhaled long-acting bronchodilators are recommended as first-line agents for maintenance therapy in patients with moderate and severe disease and those with daily symptoms. Long-acting bronchodilators improve symptoms, exercise tolerance, and health status, and reduce exacerbations in patients COPD. However, their effects on long-term decline in lung function and mortality are currently under investigation. When symptoms are not sufficiently controlled by the use of one bronchodilator, combining bronchodilators of different classes may be a more effective approach. In fact, recent evidence supports the regular use of a combination of a long-acting ß₂-adrenoceptor agonist and a long-acting anticholinergic agent in patients with severe COPD. Combining a long-acting ß₂-adrenoceptor agonist with an inhaled corticosteroid has also been shown to be more effective than the use of either agent alone. The use of theophylline has declined in recent years because of its narrow therapeutic index, and should be reserved as a third-line option in patients with very severe disease. Several novel bronchodilators are now in different stages of development for use alone or in combination with other agents.

Key Words: anticholinergics • ß₂-adrenoceptor agonists • bronchodilators • chronic obstructive pulmonary disease

This article has been cited by other articles:

				A. Gavalda, M. Miralpeix, I. Ramos, R. Otal, C. Carreno, M. Vinals, T. Domenech, C. Carcasona, B. Reyes, D. Vilella, et al. Characterization of Aclidinium Bromide, a Novel Inhaled Muscarinic Antagonist, with Long Duration of Action and a Favorable Pharmacological Profile J. Pharmacol. Exp. Ther., November 1, 2009; 331(2): 740 - 751. [Abstract] [Full Text] [PDF]

				W. C. Bailey and D. P. Tashkin Pharmacologic Therapy: Novel Approaches for Chronic Obstructive Pulmonary Disease Proceedings of the ATS, October 1, 2007; 4(7): 543 - 548. [Abstract] [Full Text] [PDF]